ASAPHEN EC 162 MG — DIN 02247550
ACETYLSALICYLIC ACID : 162 MG · PHARMASCIENCE INC · TABLET (DELAYED-RELEASE) · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ASAPHEN EC?
ASAPHEN EC 162 MG contains ACETYLSALICYLIC ACID : 162 MG. It is listed in the Health Canada Drug Product Database under DIN 02247550, held by PHARMASCIENCE INC, supplied as TABLET (DELAYED-RELEASE) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 04-Jul-2025. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
Is there a generic Acetylsalicylic Acid in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Acetylsalicylic Acid, across 23 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PHARMASCIENCE INC | 11 | 4 | ASA, ASA 81 MG, ASA DAILY LOW DOSE, ASAPHEN EC, CHEWABLE DAILY LOW DOSE ASA, +6 more | Sourceable in Canada |
| VITA HEALTH PRODUCTS INC | 3 | 3 | ASA 81 MG, ENTERIC COATED DAILY LOW DOSE ASA 81 MG, JAMP-ASA 81MG EC | Sourceable in Canada |
| BAYER INC | 2 | 2 | ASPIRIN 81MG, ASPIRIN 81MG QUICK CHEWS | Sourceable in Canada |
| PENDOPHARM DIVISION OF PHARMASCIENCE INC | 2 | 2 | ENTROPHEN, ENTROPHEN CHEWABLE | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 1 | 1 | RIVASA 81 MG EC | Sourceable in Canada |
| APOTEX INC | 2 | 0 | APO-ASA LD, COATED DAILY LOW DOSE ASA 81 MG | No marketed DIN |
| LABORATOIRES TRIANON INC. | 1 | 0 | ASA 81 MG | No marketed DIN |
| SANIS HEALTH INC | 1 | 0 | ASA EC | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 162 MG |
|---|---|
| Dosage form | TABLET (DELAYED-RELEASE) |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Acetylsalicylic Acid |
|---|---|
| ATC code | B01AC06 |
| AHFS class | 28:08.04.24 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02247550 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2247550 |
| Brand name | ASAPHEN EC |
| Generic / active ingredient | ACETYLSALICYLIC ACID : 162 MG |
| Market authorization holder | PHARMASCIENCE INC |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | B01AC06 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B01AC |
| Current status | CANCELLED POST MARKET |
| Status date | 04-Jul-2025 |
| Original market date | 2003-09-02 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 23 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ASA | 81 MG | TABLET (DELAYED-RELEASE) | PHARMASCIENCE INC | MARKETED | 02433044 |
| ASA 81 MG | 81 MG | TABLET (DELAYED-RELEASE) | VITA HEALTH PRODUCTS INC | MARKETED | 02372177 |
| ASA 81 MG | 81 MG | TABLET (DELAYED-RELEASE) | PHARMASCIENCE INC | MARKETED | 02244993 |
| ASA DAILY LOW DOSE | 81 MG | TABLET (CHEWABLE) | PHARMASCIENCE INC | MARKETED | 02394790 |
| ASPIRIN 81MG | 81 MG | TABLET (ENTERIC-COATED) | BAYER INC | MARKETED | 02237726 |
| ASPIRIN 81MG QUICK CHEWS | 81 MG | TABLET (CHEWABLE) | BAYER INC | MARKETED | 02289970 |
| ENTERIC COATED DAILY LOW DOSE ASA 81 MG | 81 MG | TABLET (DELAYED-RELEASE) | VITA HEALTH PRODUCTS INC | MARKETED | 02363127 |
| ENTROPHEN | 81 MG | TABLET (DELAYED-RELEASE) | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | 02242281 |
| ENTROPHEN CHEWABLE | 81 MG | TABLET (CHEWABLE) | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | 02243974 |
| JAMP-ASA 81MG EC | 81 MG | TABLET (ENTERIC-COATED) | VITA HEALTH PRODUCTS INC | MARKETED | 02427206 |
2 · Same class — other molecules in ATC B01AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Clopidogrel | ABBOTT-CLOPIDOGREL · ACCEL-CLOPIDOGREL · ACT CLOPIDOGREL · AG-CLOPIDOGREL · +22 more | 39 | 19 | Yes |
| Acetylsalicylic Acid | APO-ASA LD · ASA · ASA 81 MG · ASA DAILY LOW DOSE · +17 more | 23 | 12 | Yes |
| Ticagrelor | AG-TICAGRELOR · APO-TICAGRELOR · BRILINTA · JAMP TICAGRELOR · +3 more | 14 | 12 | Yes |
| Selexipag | UPTRAVI | 8 | 8 | Yes |
| Treprostinil | REMODULIN · TREPROSTINIL INJECTION | 8 | 4 | Yes |
| Epoprostenol | CARIPUL · EPOPROSTENOL FOR INJECTION · FLOLAN | 6 | 4 | Yes |
| Dipyridamole | APO-DIPYRIDAMOLE · APO-DIPYRIDAMOLE-SC TAB 25MG · APO-DIPYRIDAMOLE-SC TAB 50MG · APO-DIPYRIDAMOLE-SC TAB 75MG · +17 more | 24 | 2 | Yes |
| Eptifibatide | EPTIFIBATIDE INJECTION · INTEGRILIN | 14 | 2 | Yes |
| Tirofiban | AGGRASTAT | 2 | 1 | Yes |
| Prasugrel | EFFIENT · JAMP PRASUGREL | 2 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B01AF | Apixaban · Edoxaban · Rivaroxaban | 159 | 121 |
| B01AB | Antithrombin · Dalteparin · Danaparoid · Enoxaparin · Heparin · +3 more | 128 | 82 |
| B01AA | Acenocoumarol · Warfarin | 62 | 16 |
| B01AE | Argatroban · Bivalirudin · Dabigatran Etexilate · Lepirudin | 18 | 11 |
| B01AX | Caplacizumab · Defibrotide · Fondaparinux | 10 | 5 |
| B01AD | Alteplase · Ancrod · Anistreplase · Drotrecogin Alfa · Reteplase · +3 more | 22 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.